C-3GJZNeuroClues
eye-tracking, neurological biomarkers, AI
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3GJZ
C-3GJZC-3GJZeye-tracking, neurological biomarkers, AI
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The company states that eye movements can serve as quick, non-invasive, and robust biomarkers for neurological disease, enabling practitioners to identify disease years before visible symptoms and to follow disease progression objectively. It presents eye-tracking as scientifically grounded, clinically useful for early detection and differential diagnosis, and valuable for monitoring treatment efficacy and supporting research.
SourceNo company stance, belief, or mission is stated in this snapshot. The visible page is an OVHcloud domain-creation placeholder for neuroclues.com, showing hosting and domain-management options rather than Neuroclues company content.
SourceneuroClues states that eye movements provide objective, non-invasive, quick, and robust biomarkers that can help practitioners identify neurological diseases years before visible symptoms appear, distinguish among differential diagnoses, and follow disease progression and treatment efficacy over time.
SourceThe provided Wayback snapshot text does not contain any stated beliefs, mission, or theory from the company. It appears to be an OVH domain-creation placeholder page indicating that neuroclues.com had been created, rather than an active company website with substantive content.
Source